Top

Published in:

26-01-2024 | Schizophrenia | Psychiatry and Preclinical Psychiatric Studies - Original Article

The relationship between serum prolactin levels and cognitive function in drug-naïve schizophrenia patients: a cross-sectional study

Authors: Guoshuai Luo, Fengfeng Bai, Xuehui Qu, Yifan Jing, Shuo Wang, Zaimina Xuekelaiti, Cong Yao, Meijuan Li, Jie Li

Published in: Journal of Neural Transmission | Issue 4/2024

Abstract

This study aimed to investigate the association between serum prolactin levels and psychiatric symptoms and cognitive function in drug-naïve schizophrenia patients. The study recruited 91 drug-naïve schizophrenia patients and 67 healthy controls. Sociodemographic and clinical data were collected, and cognitive function was assessed using the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB). Serum prolactin levels were measured, and statistical analyses were performed to examine the relationship between prolactin levels, clinical symptoms, and cognitive function. The study found that drug-naïve schizophrenia patients had severe cognitive deficits compared to healthy controls across all seven domains of the MCCB. However, no correlation was found between these patients’ serum prolactin levels and clinical severity or cognitive function. The drug-naïve schizophrenia patients had significant cognitive deficits compared to healthy controls. However, there was no significant relationship between prolactin levels and symptomatology and cognition in drug-naïve schizophrenia patients.

Aringhieri S et al (2018) Molecular targets of atypical antipsychotics: from mechanism of action to clinical differences. Pharmacol Ther 192:20–41CrossRefPubMed

Brisman MH, Fetell MR, Post KD (1993) Reversible dementia due to macroprolactinoma. Case report. J Neurosurg 79(1):135–137CrossRefPubMed

Degl’Innocenti A et al (1999) The influence of prolactin response to d-fenfluramine on executive functioning in major depression. Biol Psychiatry 46(4):512–517CrossRefPubMed

Fan F et al (2019) Subcortical structures and cognitive dysfunction in first episode schizophrenia. Psychiatry Res Neuroimaging 286:69–75CrossRefPubMedPubMedCentral

Fitzgerald P, Dinan TG (2008) Prolactin and dopamine: what is the connection? A review article. J Psychopharmacol 22(2 Suppl):12–19CrossRefPubMed

García RR, Aliste F, Soto G (2018) Social cognition in schizophrenia: cognitive and neurobiological aspects. Rev Colomb Psiquiatr (engl Ed) 47(3):170–176PubMed

Hagi K et al (2021) Association between cardiovascular risk factors and cognitive impairment in people with schizophrenia: a systematic review and meta-analysis. JAMA Psychiat 78(5):510–518CrossRef

Havelka D et al (2016) Cognitive impairment and cortisol levels in first-episode schizophrenia patients. Stress 19(4):383–389CrossRefPubMed

Herceg M et al (2020) Correlation between prolactin and symptom profile in acute admitted women with recurrent schizophrenia. Psychiatr Danub 32(3–4):367–372CrossRefPubMed

Ittig S et al (2017) Sex differences in prolactin levels in emerging psychosis: indication for enhanced stress reactivity in women. Schizophr Res 189:111–116CrossRefPubMed

Jones AS et al (2021) Prolactin ordering patterns in psychiatric inpatients and the impact this has on patient management. Australas Psychiatry 29(3):282–285CrossRefPubMed

Jose J et al (2015) Association between prolactin and thyroid hormones with severity of psychopathology and suicide risk in drug free male schizophrenia. Clin Chim Acta 444:78–80CrossRefPubMed

Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13(2):261–276CrossRefPubMed

Labad J (2019) The role of cortisol and prolactin in the pathogenesis and clinical expression of psychotic disorders. Psychoneuroendocrinology 102:24–36CrossRefPubMed

Lim K et al (2021) Large-scale evaluation of the Positive and Negative Syndrome Scale (PANSS) symptom architecture in schizophrenia. Asian J Psychiatr 62:102732CrossRefPubMed

Marken PA, Haykal RF, Fisher JN (1992) Management of psychotropic-induced hyperprolactinemia. Clin Pharm 11(10):851–856PubMed

McGregor C, Riordan A, Thornton J (2017) Estrogens and the cognitive symptoms of schizophrenia: Possible neuroprotective mechanisms. Front Neuroendocrinol 47:19–33CrossRefPubMed

Miller R (2009) Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: part I. Curr Neuropharmacol 7(4):302–314CrossRefPubMedPubMedCentral

Montalvo I et al (2014) Increased prolactin levels are associated with impaired processing speed in subjects with early psychosis. PLoS One 9(2):e89428CrossRefPubMedPubMedCentral

Montalvo I et al (2018) Improvement in cognitive abilities following cabergoline treatment in patients with a prolactin-secreting pituitary adenoma. Int Clin Psychopharmacol 33(2):98–102CrossRefPubMed

Moore L et al (2013) Serum testosterone levels are related to cognitive function in men with schizophrenia. Psychoneuroendocrinology 38(9):1717–1728CrossRefPubMed

Mortimer AM (2007) Relationship between estrogen and schizophrenia. Expert Rev Neurother 7(1):45–55CrossRefPubMed

Penadés R et al (2015) The search for new biomarkers for cognition in schizophrenia. Schizophr Res Cogn 2(4):172–178CrossRefPubMedPubMedCentral

Puljic K et al (2021) The association between prolactin concentration and aggression in female patients with schizophrenia. World J Biol Psychiatry 22(4):301–309CrossRefPubMed

Rajkumar RP (2014) Prolactin and psychopathology in schizophrenia: a literature review and reappraisal. Schizophr Res Treat 2014:175360

Sheffield JM, Karcher NR, Barch DM (2018) Cognitive deficits in psychotic disorders: a lifespan perspective. Neuropsychol Rev 28(4):509–533CrossRefPubMedPubMedCentral

Shi C et al (2013) An ecologically valid performance-based social functioning assessment battery for schizophrenia. Psychiatry Res 210(3):787–793CrossRefPubMed

Shi C et al (2015) The MATRICS Consensus Cognitive Battery (MCCB): co-norming and standardization in China. Schizophr Res 169(1–3):109–115CrossRefPubMedPubMedCentral

Shi C et al (2019) What is the optimal neuropsychological test battery for schizophrenia in China? Schizophr Res 208:317–323CrossRefPubMedPubMedCentral

Voráčková V et al (2021) Cognitive profiles of healthy siblings of first-episode schizophrenia patients. Early Interv Psychiatry 15(3):554–562CrossRefPubMed

Vuk Pisk S et al (2019) Hyperprolactinemia—side effect or part of the illness. Psychiatr Danub 31(Suppl 2):148–152PubMed

Wasnik V et al (2019) Serum prolactin level and its correlation with psychopathology in drug free/drug naïve schizophrenia a case control study. Asian J Psychiatr 39:1–5CrossRefPubMed

Yao S et al (2017) Cognitive function and serum hormone levels are associated with gray matter volume decline in female patients with prolactinomas. Front Neurol 8:742CrossRefPubMed

Zhang XY et al (2002) Risperidone-induced increase in serum prolactin is correlated with positive symptom improvement in chronic schizophrenia. Psychiatry Res 109(3):297–302CrossRefPubMed

Zhang X et al (2020) Glucose disturbances, cognitive deficits and white matter abnormalities in first-episode drug-naive schizophrenia. Mol Psychiatry 25(12):3220–3230CrossRefPubMed

Zhu MH et al (2022) Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial. Mil Med Res 9(1):59PubMedPubMedCentral

Title: The relationship between serum prolactin levels and cognitive function in drug-naïve schizophrenia patients: a cross-sectional study
Authors: Guoshuai Luo
Fengfeng Bai
Xuehui Qu
Yifan Jing
Shuo Wang
Zaimina Xuekelaiti
Cong Yao
Meijuan Li
Jie Li
Publication date: 26-01-2024
Publisher: Springer Vienna
Keyword: Schizophrenia
Published in: Journal of Neural Transmission / Issue 4/2024
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-024-02748-4

At a glance: The STEP trials

Springer Medicine

The relationship between serum prolactin levels and cognitive function in drug-naïve schizophrenia patients: a cross-sectional study

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2024

Mild cognitive impairment in Huntington’s disease: challenges and outlooks

Prof. DDr. Gregor K. Wenning (1964–2024)

Validation of the Italian version of the Parkinson’s Disease- Cognitive Functional Rating Scale

Association between autonomic dysfunction with motor and non-motor symptoms in patients with Parkinson's disease

High-dose glucocorticoids in COVID-19 patients with acute encephalopathy: clinical and imaging findings in a retrospective cohort study

Combined light and electron microscopy (CLEM) to quantify methamphetamine-induced alpha-synuclein-related pathology